HopeStage
Back to all studies
RecruitingNCT06786624

NBI-1065845 added to medication for major depression

About this titleRead the official source — NCT06786624

This study evaluates the safety and effectiveness of NBI-1065845 for people with depression.

Medication studyAges 18+United States
The study in practice

Understand this study

What is this study about?

This study evaluates the safety and effectiveness of NBI-1065845 for people with depression.

Who could participate?

This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.

Listed locations
Little Rock and 17 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: January 22, 2025
Recruitment status
Recruiting
Enrollment listed in the registry
200
Sponsor
Neurocrine Biosciences
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
Over 18 Years
Official registry ID
NCT06786624
Official title
Show the full official title

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)

Recruitment & locations

Currently recruiting

Little Rock · Garden Grove · Orange

15 more locations
  • Pico Rivera
  • San Diego
  • Upland
  • Hollywood
  • Maitland
  • Boston
  • Watertown
  • Mount Kisco
  • Avon Lake
  • Westlake
  • Dallas
  • Houston
  • Richmond
  • The Woodlands
  • Everett

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

This study evaluates the safety and effectiveness of NBI-1065845 for people with depression.

Who is behind this study?

The study sponsor is Neurocrine Biosciences, a biotech company.

Does this study involve medication?

Yes. The study involves medication, including NBI-1065845 and Placebo.

Who can participate?

This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies